Unlikely Hopper is waiting for a CDH 17 update as the first patient dosed is actually the first and only one that can be assessed. Of course after 28 / 35 days one can determine if there are safety issues but even if that one had a complete response after 4 weeks CHM wouldn't be allowed to use that result straight away. Took them a few months over at IMU before allowed to go public with the 2 responses for the bile duct patients.
He himself set September as the issue dead line, not sure how holders will react if that CR gets postponed. Strange, never have been eagerly awaiting a CR to come. Yep, desperate times, desperate expectations.
GLTA
CHM Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)